CN104711223A - Preparation of platelet washing solution - Google Patents
Preparation of platelet washing solution Download PDFInfo
- Publication number
- CN104711223A CN104711223A CN201510179788.1A CN201510179788A CN104711223A CN 104711223 A CN104711223 A CN 104711223A CN 201510179788 A CN201510179788 A CN 201510179788A CN 104711223 A CN104711223 A CN 104711223A
- Authority
- CN
- China
- Prior art keywords
- platelet
- solution
- thrombocyte
- washing solution
- washings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a preparation of a platelet washing solution. The platelet washing solution comprises two solutions as follows: 500ml of a bicarbonate Ringer solution and 20-30ml of an ACD-A anticoagulant. The platelet washing solution prepared from 500ml of the bicarbonate Ringer solution and 25ml of the ACD-A anticoagulant is optimal in washing effect. According to the preparation of the platelet washing solution, two solutions with permission to the clinical application at present are mixed at a certain ratio; the platelet washing solution is used for washing and preparing plasma-poor platelet; by virtue of the clinical application of the plasma-poor platelet, the untoward effects of platelet transfusion caused by plasma proteins can be solved. The platelet washing solution is simple in components and liable to depolymerize; the recovery rate of the platelet is increased; the agglomeration force is improved; the safety is guaranteed.
Description
Technical field
The present invention relates to medical field, specifically a kind of thrombocyte washings formula.
Background technology
Platelet transfusion is applicable to the hemorrhage of prevention and therapy thrombopenia or defective platelet function patient, is supportive treatment important clinically.Being applied to clinical thrombocyte is at present all be suspended in blood plasma, containing a certain amount of plasma proteins, white corpuscle and other biological active substance, it is the major cause causing Adverse transfusion reaction, anaphylaxis in various degree, nonhemolytic febrific reaction, even transfusion-associated acute lung injury is there will be after some patients infusion, fatal danger may be caused to patient, and misgivings are felt to blood products therapies again.
Adopt machine to adopt washing platelet to the patient reacted, the generation again that this type of reacts can be avoided.Current main wash thrombocyte preparation adopts the parameter of centrifuging and change automatic blood cell separating machine directly to gather few slurry thrombocyte, and the washings adopted comprises physiological saline, self-control blood platelet additive solution (PAS).
Centrifugal washing preparation starches thrombocyte less, and shearing force time centrifugal is very large on thrombocyte impact, and there will be platelet counts and reduce, the rate of recovery declines, depolymerization difficulty, is externally activated, degradation situation under aggregation force.Improvement thrombocyte separating machine parameter becomes collection and starches thrombocyte main method less.But there is different shortcoming in the washings used at present.Physiological saline does not possess colloids adhere and the proportion of plasma proteins, and when being washings with physiological saline and replacing blood plasma as hematoblastic suspension medium, thrombocyte can not even suspension and be easy to sedimentation in physiological saline.Make various formula washings by oneself due to each complicated component, and be autogamy, infusion security cannot ensure.
Summary of the invention
The object of the present invention is to provide the thrombocyte washings formula that a kind of composition is simple, safety is secure, to solve the problem proposed in above-mentioned background technology.
For achieving the above object, the invention provides following technical scheme:
A thrombocyte washings formula, has following two kinds of solution compositions: 500ml supercarbonate Ringer's solution and 20-30ml ACD-A antithrombotics; The composition contained in every 500ml supercarbonate Ringer's solution: 2.92g NaCl, 0.15g KCl, 0.11g CaCl
22H
2o, 0.10g MgCl
26H
2o, 1.175g NaHCO
3, 0.10g Sodium Citrate, usp, Dihydrate Powder, solvent is distilled water.Every 1000mlACD-A antithrombotics composition: 22g bis-citric acid monohydrate trisodium, 8g Citric Acid Monohydrate, 24.5g DEXTROSE MONOHYDRATE BP, solvent is distilled water.
As the further scheme of the present invention: described thrombocyte washings formula, by following two kinds of solution compositions: 500ml supercarbonate Ringer's solution and 25ml ACD-A antithrombotics, obtained washings consists of the following composition: NaCl 95.2mmol/L, KCl 3.8mmol/L, MgCl
20.9mmol/L, NaHCO
326.6mmol/L, glucose 5.8mmol/L, Trisodium Citrate 4.2mmol/L, citric acid 1.8mmol/L, CaCl
21.4mmol/L, solvent is distilled water.
Compared with prior art, the invention has the beneficial effects as follows: two kinds of liquid of access clinical application at present configure by the present invention according to a certain percentage, starch thrombocyte less in order to washing preparation, for clinical, solve the platelet transfusion untoward reaction because plasma proteins causes.Present component is simple, and recovery rate of blood platelet improves, depolymerization is easy, aggregation force improves, and safety is secure.
Embodiment
Below in conjunction with the embodiment of the present invention, be clearly and completely described the technical scheme in the embodiment of the present invention, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, when preparing thrombocyte washings, the two kinds of liquid used: 1) supercarbonate Ringer's solution (bicarbonated Ringer's solution, BRS), large tomb pharmacy 500ml packs, and contains: 2.92g NaCl, 0.15g KCl, 0.11g CaCl
22H
2o, 0.10g MgCl
26H
2o, 1.175g NaHCO
3, 0.10g Sodium Citrate, usp, Dihydrate Powder.2) ACD-A antithrombotics (Shandong prestige is high), 1000ml packs, and contains: 22g bis-citric acid monohydrate trisodium, 8g Citric Acid Monohydrate, 24.5g DEXTROSE MONOHYDRATE BP.
Collocation method: get 20ml ACD-A antithrombotics and mix with 500ml BRS, be configured to BRS-A solution, is this institute configuration thrombocyte washings.Above-mentioned two kinds of liquid are clinical approval medication, and aseptic mixing of plugging into, can be used for washing platelet, be directly used in clinical.
Thrombocyte washing and detection: after 2 parts of identical Platelets Pheresis/Apheresis platelets Homogeneous phase mixing of abo blood group, equivalent is divided into 2 parts, and portion in contrast, is positioned in 22-24 ° of C platelet oscillation storage box and preserves, another part of measurement volumes (weight/1.03), by aseptic three joint bag of plugging into, mix with 250ml washings of filling a prescription, the centrifugal 10min of 2560g room temperature, empty bag clamp-oned by supernatant liquor as far as possible, heat seal discards, and it is resuspended again to add washings, and final volume is consistent with before washing.Room temperature puts into platelet oscillation storage box after placing 30min.In latter 1,3,5 day of washing, get washing group and each 2ml of control group sample, detect damping fluid and platelet parameter.Result is as shown in table 1.
Table 1
Embodiment 2
In the embodiment of the present invention, when preparing thrombocyte washings, get 25ml ACD-A antithrombotics and mix with 500ml BRS, be configured to BRS-A solution, be the present invention and configure thrombocyte washings.Above-mentioned two kinds of liquid are clinical approval medication, and aseptic mixing of plugging into, can be used for washing platelet, be directly used in clinical.Other concrete steps are identical with embodiment 1, repeat no more.Result is as shown in table 2.
Table 2
Embodiment 3
In the embodiment of the present invention, when preparing thrombocyte washings, get 30ml ACD-A antithrombotics and mix with 500ml BRS, be configured to BRS-A solution, be this institute configuration thrombocyte washings.Other concrete steps are identical with embodiment 1, repeat no more.Result is as shown in table 3.
Table 3
Embodiment 4
In the embodiment of the present invention, when preparing thrombocyte washings, get 22ml ACD-A antithrombotics and mix with 500ml BRS, be configured to BRS-A solution, be this institute configuration thrombocyte washings.Other concrete steps are identical with embodiment 1, repeat no more.Result is as shown in table 4.
Table 4
Embodiment 5
In the embodiment of the present invention, when preparing thrombocyte washings, get 28ml ACD-A antithrombotics and mix with 500ml BRS, be configured to BRS-A solution, be this institute configuration thrombocyte washings.Other concrete steps are identical with embodiment 1, repeat no more.Result is as shown in table 5.
Table 5
As can be seen from table 1-table 5,
1) compared with Platelets Pheresis/Apheresis platelets, mean platelet volume (MPV) is without noticeable change;
2) compared with Platelets Pheresis/Apheresis platelets, washing platelet does not significantly activate (CD62P, CD42b per-cent is without significant difference);
3) washing platelet buffer system ideal (index such as pH, lactic acid, supercarbonate);
4) washing platelet complete function (aggregation rate, adhesion rate indifference compared with Platelets Pheresis/Apheresis platelets).
The present invention adopts centrifugal washing to determine two kinds of liquid best-fit ratios, and the effect that discovery 25ml ACD-A antithrombotics and 500ml BRS are mixed with thrombocyte washings is best.And this best-fit is applied on automatic blood cell separating machine than the thrombocyte washings of preparation, plasma residence is down to 2.1%; Recovery rate of blood platelet reaches 92.1%.
To those skilled in the art, obviously the invention is not restricted to the details of above-mentioned one exemplary embodiment, and when not deviating from spirit of the present invention or essential characteristic, the present invention can be realized in other specific forms.Therefore, no matter from which point, all should embodiment be regarded as exemplary, and be nonrestrictive, scope of the present invention is limited by claims instead of above-mentioned explanation, and all changes be therefore intended in the implication of the equivalency by dropping on claim and scope are included in the present invention.
In addition, be to be understood that, although this specification sheets is described according to embodiment, but not each embodiment only comprises an independently technical scheme, this narrating mode of specification sheets is only for clarity sake, those skilled in the art should by specification sheets integrally, and the technical scheme in each embodiment also through appropriately combined, can form other embodiments that it will be appreciated by those skilled in the art that.
Claims (2)
1. a thrombocyte washings formula, is characterized in that, by following two kinds of solution compositions: 500ml supercarbonate Ringer's solution and 20-30ml ACD-A antithrombotics; The composition contained in every 500ml supercarbonate Ringer's solution: 2.92g NaCl, 0.15g KCl, 0.11g CaCl
22H
2o, 0.10g MgCl
26H
2o, 1.175g NaHCO
3, 0.10g Sodium Citrate, usp, Dihydrate Powder, solvent is distilled water; Every 1000mlACD-A antithrombotics composition: 22g bis-citric acid monohydrate trisodium, 8g Citric Acid Monohydrate, 24.5g DEXTROSE MONOHYDRATE BP, solvent is distilled water.
2. thrombocyte washings formula according to claim 1, is characterized in that, by following two kinds of solution compositions: 500ml supercarbonate Ringer's solution and 25ml ACD-A antithrombotics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510179788.1A CN104711223A (en) | 2015-04-16 | 2015-04-16 | Preparation of platelet washing solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510179788.1A CN104711223A (en) | 2015-04-16 | 2015-04-16 | Preparation of platelet washing solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104711223A true CN104711223A (en) | 2015-06-17 |
Family
ID=53410942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510179788.1A Pending CN104711223A (en) | 2015-04-16 | 2015-04-16 | Preparation of platelet washing solution |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104711223A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263266A (en) * | 1999-02-08 | 2000-08-16 | 刘剑雄 | Development of whole blood quality control substance in cell three-classification of hematology |
| CN1883504A (en) * | 2005-06-22 | 2006-12-27 | 苏正尧 | Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition |
| EP2597947A2 (en) * | 2010-07-27 | 2013-06-05 | Biovec Transfusion, LLC | Composition for preserving platelets and method of use thereof |
-
2015
- 2015-04-16 CN CN201510179788.1A patent/CN104711223A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263266A (en) * | 1999-02-08 | 2000-08-16 | 刘剑雄 | Development of whole blood quality control substance in cell three-classification of hematology |
| CN1883504A (en) * | 2005-06-22 | 2006-12-27 | 苏正尧 | Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition |
| EP2597947A2 (en) * | 2010-07-27 | 2013-06-05 | Biovec Transfusion, LLC | Composition for preserving platelets and method of use thereof |
Non-Patent Citations (2)
| Title |
|---|
| SHINJI OIKAWA等: "Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer"s solution with less than 5% plasma", 《TRANSFUSION》 * |
| WALTER E. KELLY等: "Washing platelets in neutral, calcium-free, Ringer"s acetate", 《TRANSFUTION》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strauss et al. | Pentastarch may cause fewer effects on coagulation than hetastarch | |
| AU2002356899B2 (en) | Bicarbonate-based solutions for dialysis therapies | |
| JP5876042B2 (en) | Dialysis precursor composition | |
| Strauss | Volume replacement and coagulation: a comparative review | |
| CN102225063B (en) | Pantoprazole sodium composition for injection | |
| CA2568180C (en) | Medical solution, method for producing and use thereof | |
| Sörensen et al. | Pediatric apheresis with a novel apheresis device with electronic interface control | |
| CN102631665B (en) | Pharmaceutical composition of alanyl glutamine injection and compound amino acid injection | |
| Veljkovic et al. | Mobilization and harvesting of peripheral blood stem cells in pediatric patients with solid tumors | |
| CN104711223A (en) | Preparation of platelet washing solution | |
| CN105726565A (en) | Sodium citrate Ringer injecta packaged by non-PVC plastics and preparation process of sodium citrate Ringer injecta | |
| Dionigi et al. | Effect of perioperative blood transfusion on clinical outcomes in hepatic surgery for cancer | |
| AU2007203585A1 (en) | Platelet Additive Solution | |
| Massicotte et al. | Con: low central venous pressure during liver transplantation | |
| Sohn et al. | Application of the continuous autotransfusion system (CATS) to prevent transfusion-related hyperkalemia following hyperkalemic cardiac arrest in an infant-A case report | |
| CN204745121U (en) | Supplementary bag of washing of red blood cell blood bag | |
| Kaplan et al. | Therapeutic apheresis (plasma exchange or cytapheresis): Complications | |
| Ferroni et al. | The use of intraoperative cell salvage in urologic oncology | |
| CN101485886B (en) | Blood platelet additive solution and preparation method thereof | |
| CN103169957A (en) | Nano thrombin and preparation method thereof | |
| Tucci et al. | Transfusion medicine | |
| CN103536552A (en) | Cisatracurium besilate composition freeze-dried powder for injection | |
| CN204543022U (en) | A kind of collection stem cell blood bagging apparatus | |
| Kulkarni et al. | Pediatric transfusion therapy: practical considerations | |
| van Prooijen et al. | Clinical experience with transfusion of leukocyte-poor platelet concentrates prepared by filtration with prostacyclin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150617 |